# Stupp Trial (EORTC 26981/22981) - Original FDA Approval Data

**Source**: New England Journal of Medicine, 2005
**Citation**: Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
**DOI**: 10.1056/NEJMoa043330
**PubMed ID**: 15758009

## TRIAL DESIGN

### Study Population
- **Total patients**: 573 patients with newly diagnosed glioblastoma multiforme
- **Randomization**: 2:1 ratio
- **Treatment arm**: 287 patients (RT + TMZ)
- **Control arm**: 286 patients (RT alone)

### Inclusion Criteria
- Age 18-70 years
- WHO performance status 0-2
- Newly diagnosed, histologically confirmed glioblastoma multiforme
- Adequate bone marrow, liver, and renal function

### Exclusion Criteria
- Prior chemotherapy or radiotherapy for brain tumor
- Concurrent malignancy
- Inability to take oral medications

## TREATMENT PROTOCOL

### Radiotherapy (Both Arms)
- **Dose**: 60 Gy in 30 fractions
- **Schedule**: 5 days per week for 6 weeks
- **Target**: Gross tumor volume + 2-3 cm margin

### Temozolomide Protocol (Treatment Arm)

#### Concomitant Phase
- **Dose**: 75 mg/m² daily
- **Duration**: During entire radiotherapy period (up to 49 days)
- **Administration**: Oral, 1 hour before radiotherapy

#### Maintenance Phase
- **Start**: 4 weeks after completion of radiotherapy
- **Cycle 1**: 150 mg/m² × 5 days (28-day cycle)
- **Cycles 2-6**: 200 mg/m² × 5 days (if cycle 1 tolerated)
- **Total**: Up to 6 cycles

## PRIMARY RESULTS

### Overall Survival (Primary Endpoint)
- **TMZ + RT**: 14.6 months (median)
- **RT alone**: 12.1 months (median)
- **Hazard ratio**: 0.63 (95% CI: 0.52-0.75)
- **P-value**: <0.0001
- **Risk reduction**: 37%

### Progression-Free Survival
- **TMZ + RT**: 6.9 months (median)
- **RT alone**: 5.0 months (median)
- **Hazard ratio**: 0.54 (95% CI: 0.46-0.64)
- **P-value**: <0.0001

### Survival at Key Time Points
**6-month survival**:
- TMZ + RT: 84%
- RT alone: 68%

**12-month survival**:
- TMZ + RT: 61%
- RT alone: 47%

**24-month survival**:
- TMZ + RT: 26%
- RT alone: 10%

## SAFETY PROFILE

### Grade 3-4 Hematologic Toxicity
- **Neutropenia**: 7% (TMZ arm) vs 0% (RT alone)
- **Thrombocytopenia**: 11% (TMZ arm) vs 1% (RT alone)
- **Lymphocytopenia**: 16% (TMZ arm) vs 3% (RT alone)

### Non-Hematologic Toxicity
- **Fatigue Grade 3-4**: 15% (TMZ arm) vs 9% (RT alone)
- **Nausea/Vomiting**: Generally Grade 1-2
- **Infection**: 9% (TMZ arm) vs 4% (RT alone)

### Treatment Discontinuation
- **Concomitant phase**: 8% discontinued TMZ due to toxicity
- **Maintenance phase**: 21% discontinued due to toxicity

## MOLECULAR ANALYSIS

### MGMT Promoter Methylation
**Methylated MGMT**:
- TMZ + RT: 21.7 months (median OS)
- RT alone: 15.3 months (median OS)
- Benefit: 6.4 months improvement

**Unmethylated MGMT**:
- TMZ + RT: 12.7 months (median OS)
- RT alone: 11.8 months (median OS)
- Benefit: 0.9 months improvement

### Clinical Significance
- **Predictive marker**: MGMT methylation predicts benefit from TMZ
- **Treatment recommendation**: TMZ beneficial regardless of MGMT status

## QUALITY OF LIFE

### Measurements
- **Tool**: EORTC QLQ-C30 and QLQ-BN20
- **Assessment**: Baseline and every 3 months
- **Results**: No significant deterioration in QOL with TMZ addition

## STATISTICAL METHODS

### Sample Size Calculation
- **Power**: 80%
- **Alpha**: 0.05
- **Hazard ratio**: 0.75
- **Required events**: 416 deaths

### Analysis
- **Primary**: Intention-to-treat analysis
- **Statistical test**: Log-rank test
- **Multivariate**: Cox proportional hazards model

## FDA IMPACT

### Regulatory Approval
- **FDA approval date**: March 15, 2005
- **Indication**: Newly diagnosed glioblastoma multiforme
- **Basis**: This pivotal Phase III trial

### Standard of Care
- **Global adoption**: Became worldwide standard (Stupp protocol)
- **Practice change**: Established concurrent chemoradiotherapy
- **Survival benchmark**: 14.6 months median OS became reference

## LONG-TERM FOLLOW-UP

### 5-Year Results (Updated Analysis)
- **5-year survival**: 9.8% (TMZ + RT) vs 1.9% (RT alone)
- **Durability**: Benefit maintained long-term
- **Confirmation**: Treatment effect sustained

### Extended Analysis
- **Median follow-up**: 61 months
- **Consistency**: Results remained significant
- **Impact**: Confirmed clinical benefit

## CLINICAL IMPLICATIONS

### Treatment Algorithm
1. **Surgery**: Maximal safe resection
2. **Recovery**: 3-6 weeks post-surgery
3. **Concomitant**: RT + TMZ × 6-7 weeks
4. **Recovery**: 4-week break
5. **Maintenance**: TMZ × 6 cycles

### Patient Selection
- **Age**: Originally 18-70 years (later extended)
- **Performance status**: KPS ≥60 or WHO 0-2
- **Organ function**: Adequate bone marrow, liver, kidney

### Monitoring Requirements
- **Concomitant**: Weekly CBC
- **Maintenance**: CBC day 22 and 29 of each cycle
- **Toxicity**: Standard oncology monitoring

---

*This trial established temozolomide as standard therapy for newly diagnosed glioblastoma and led to FDA approval. The protocol described here (Stupp protocol) remains the backbone of GBM treatment worldwide.*